Literature DB >> 9662591

Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis.

P N Hawkins1, C Aprile, G Capri, L Viganò, E Munzone, L Gianni, M B Pepys, G Merlini.   

Abstract

Radiolabelled serum amyloid P component (SAP) is a specific tracer for amyloid. Iodine-123 has ideal physical characteristics for scintigraphy but is expensive and not widely available. Here we report serial imaging and turnover studies in which we labelled SAP with iodine-131, a cheap alternative isotope which would be expected to yield poorer images but permit more prolonged turnover measurements. Imaging and plasma clearance and whole body retention (WBR) of tracer were studied for up to 7 days in ten patients with proven systemic AL amyloidosis and two patients in whom the diagnosis was suspected, after i.v. administration of about 37 MBq of 131I-SAP. Normal blood pool images were obtained in the latter two subjects and amyloidosis was subsequently refuted histologically. WBR at 48 h was <60% and 6-h plasma activity was >65% of the injected dose (i.d.). Among the other ten patients, amyloid deposits were identified in the spleen in eight cases, liver in five and kidneys in four; other sites that gave positive results included bone, joints and soft tissues, and the myocardium in one case. Up to 95% of the tracer localised into amyloid within 6-h, and the values for WBR became progressively more discriminating during the study period, exceeding the normal reference value (<25%) in all cases by day 7. The optimal imaging time was found to be between 24 and 48 h. The duration of the study enabled us to measure the tracer elimination half-life which was increased in all cases by up to tenfold. Follow-up studies performed after 2-24 months in four patients who were treated with iododoxorubicin showed regression of amyloid in one patient and a small increase in one case; in the other two patients the imaging and turnover studies were identical to baseline. Despite its unfavourable imaging characteristics, 131I-SAP produced diagnostic scans in every patient in this series and, coupled with the detailed turnover information, is adequate for monitoring disease progress.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9662591     DOI: 10.1007/s002590050272

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  10 in total

1.  Uptake of technetium 99m HDP in cardiac amyloidosis.

Authors:  Jan Kulhanek; Assad Movahed
Journal:  Int J Cardiovasc Imaging       Date:  2003-06       Impact factor: 2.357

2.  Subacute liver failure secondary to amyloid light-chain amyloidosis.

Authors:  Theresa J Hydes; Richard J Aspinall
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-03

3.  SPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies.

Authors:  Jonathan S Wall; Tina Richey; Alan Stuckey; Robert Donnell; Arie Oosterhof; Toin H van Kuppevelt; Nicole C Smits; Stephen J Kennel
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

Review 4.  Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment.

Authors:  David C Seldin; John L Berk; Flora Sam; Vaishali Sanchorawala
Journal:  Heart Fail Clin       Date:  2011-05-20       Impact factor: 3.179

Review 5.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

6.  Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT.

Authors:  Jonathan S Wall; Tina Richey; Angela Williams; Alan Stuckey; Dustin Osborne; Emily Martin; Stephen J Kennel
Journal:  Mol Imaging Biol       Date:  2012-08       Impact factor: 3.488

Review 7.  What amyloid ligands can tell us about molecular polymorphism and disease.

Authors:  Harry LeVine; Lary C Walker
Journal:  Neurobiol Aging       Date:  2016-03-24       Impact factor: 4.673

8.  Lysozyme amyloidosis - a case report and review of the literature.

Authors:  Christopher Pleyer; Jan Flesche; Fahad Saeed
Journal:  Clin Nephrol Case Stud       Date:  2015-12-28

9.  Generation and characterization of anti-AA amyloid-specific monoclonal antibodies.

Authors:  Jonathan S Wall; Stephen J Kennel; Tina Richey; Amy Allen; Alan Stuckey; Deborah T Weiss; Sallie D Macy; Robin Barbour; Peter Seubert; Alan Solomon; Dale Schenk
Journal:  Front Immunol       Date:  2011-08-08       Impact factor: 7.561

Review 10.  The Development of Serum Amyloid P as a Possible Therapeutic.

Authors:  Darrell Pilling; Richard H Gomer
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.